Dambrine Ginette, Labaille Jennifer, Boissel Élodie, Dupuy Catherine, Rasschaert Denis
Équipe transcription et lymphome viro-induit (TLVI), UMR 7261 CNRS/Université François-Rabelais de Tours, Parc de Grandmont, 37200 Tours, France.
Virologie (Montrouge). 2016 Oct 1;20(5):273-286. doi: 10.1684/vir.2016.0670.
Marek's disease (MD) virus (MDV) is an alphaherpesvirus that causes a rapid-onset T-cell lymphoma in chickens. In order to preserve the viability of poultry industry, non sterilizing vaccines have been used since fifty years, preventing lymphoma development but leading to an imperfect control of MD. Vaccination has been accompanied with the increase in virulence of MDV forcing the development of new vaccine formulations. Several loci of MDV genome are variable and have evolved in link with virulence of MDV strains. It has been shown that MDV is in fact constituted by a dynamic population of genetic variants with a distribution linked to viral strain phenotype. In this context, we have shown that CVI988/Rispens vaccine, still the most efficient one against hypervirulent MDV strains, is composed of twenty variants, variable from one batch to another, evolving likely as RNA virus quasispecies.
马立克氏病（MD）病毒（MDV）是一种α疱疹病毒，可在鸡体内引发快速发作的T细胞淋巴瘤。为了维持家禽业的生存能力，五十年来一直使用非灭菌疫苗，这种疫苗可预防淋巴瘤的发展，但对MD的控制并不完美。疫苗接种伴随着MDV毒力的增加，这促使人们开发新的疫苗配方。MDV基因组的几个位点是可变的，并且与MDV毒株的毒力相关联地进化。已经表明，MDV实际上是由一群动态的遗传变异体组成，其分布与病毒株表型相关。在这种情况下，我们已经表明，CVI988/Rispens疫苗仍然是对抗超强毒MDV毒株最有效的疫苗，它由二十种变异体组成，不同批次之间存在差异，可能像RNA病毒准种一样进化。
